CLSD — Clearside Biomedical Share Price
0.000.00%
Last trade - 00:00- $86.70m
- $57.34m
- $8.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -86.36% | ||
| Return on Equity | n/a | ||
| Operating Margin | -322.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.17 | 7.89 | 29.57 | 1.33 | 8.23 | 0.55 | 2.98 | 207.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Directors
- William Humphries NEC (55)
- George Lasezkay PRE (69)
- Charles Deignan CFO (56)
- Thomas Ciulla OTH (57)
- Richard Croarkin IND (66)
- Jeffrey Edwards IND (61)
- Nancy Hutson IND (71)
- Christy Shaffer IND (63)
- Clay Thorp IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 26th, 2011
- Public Since
- June 2nd, 2016
- No. of Shareholders
- 7
- No. of Employees
- 30
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 74,745,572
- Address
- 900 North Point Parkway, Suite 200, ALPHARETTA, 30005
- Web
- https://clearsidebio.com/
- Phone
- +1 6782703631
- Contact
- Jenny Kobin
- Auditors
- Ernst & Young LLP
Upcoming Events for CLSD
Q4 2024 Clearside Biomedical Inc Earnings Release
Similar to CLSD
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Clearside Biomedical share price?
As of Today at 19:59 UTC, shares in Clearside Biomedical are trading at $1.16. This share price information is delayed by 15 minutes.
How has the Clearside Biomedical share price performed this year?
Shares in Clearside Biomedical last closed at $1.16 and the price had moved by +38.1% over the past 365 days. In terms of relative price strength the Clearside Biomedical share price has outperformed the S&P500 Index by +3.2% over the past year.
What are the analyst and broker recommendations for Clearside Biomedical?
The overall consensus recommendation for Clearside Biomedical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Clearside Biomedical dividend yield?
Clearside Biomedical does not currently pay a dividend.
Does Clearside Biomedical pay a dividend?
Clearside Biomedical does not currently pay a dividend.
When does Clearside Biomedical next pay dividends?
Clearside Biomedical does not currently pay a dividend.
How do I buy Clearside Biomedical shares?
To buy shares in Clearside Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clearside Biomedical?
As of the previous close price of $1.16, shares in Clearside Biomedical had a market capitalisation of $86.70m.
Where are Clearside Biomedical shares listed?
Here are the trading details for Clearside Biomedical:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CLSD
What kind of share is Clearside Biomedical?
Based on an overall assessment of its quality, value and momentum Clearside Biomedical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clearside Biomedical share price forecast for 2024?
The analyst consensus target price for shares in Clearside Biomedical is $5.57. That is 380.17% above the last closing price of $1.16.
Analysts covering Clearside Biomedical currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
Find out moreWhat is the trend in the Clearside Biomedical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clearside Biomedical. Over the past six months, its share price has underperformed the S&P500 Index by -30.72%.
As of the last closing price of $1.16, shares in Clearside Biomedical were trading -8.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clearside Biomedical PE Ratio?
The Clearside Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clearside Biomedical?
Clearside Biomedical's management team is headed by:
- William Humphries - NEC
- George Lasezkay - PRE
- Charles Deignan - CFO
- Thomas Ciulla - OTH
- Richard Croarkin - IND
- Jeffrey Edwards - IND
- Nancy Hutson - IND
- Christy Shaffer - IND
- Clay Thorp - IND